C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice

Laboratory Investigation

Volumn 91, Issue 6, 2011, Pages 837-851

  Li, Zi ^a   Chung, Arthur C K ^b   Zhou, Li ^a   Huang, Xiao R ^b   Liu, Fei ^a   Fu, Ping ^a   Fan, J M ^a   Szalai, Alexander J ^c   Lan, Hui Y ^b  

^a SICHUAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c University of Alabama at Birmingham   (United States)

Author keywords

CRP; NF B; renal fibrosis and inflammation; TGF Smad; UUO

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; MACROPHAGE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; URETER OBSTRUCTION; WILD TYPE;

EID: 79957599702     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.42     Document Type: Article

References (46)

1. Pecoits-Filho R, Sylvestre LC, Stenvinkel P. Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 2005;20:714-720. (Pubitemid 40663151)
2. Kalantar-Zadeh K, Stenvinkel P, Pillon L, et al. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003;10: 155-169. (Pubitemid 38016849)
3. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005;23:72-78. (Pubitemid 40082247)
4. Szalai AJ, McCrory MA. Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunol Res 2002;26:279-287. (Pubitemid 35177504)
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
7. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-655. (Pubitemid 38198873)
8. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003;108:512-515. (Pubitemid 36961161)
9. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in Creactive protein overexpressing mice. Atherosclerosis 2008;201: 318-325.
10. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of Creactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
11. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004;109:2116-2122. (Pubitemid 38620221)
12. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of Creactive protein. Circulation 2002;105:1890-1896. (Pubitemid 34437614)
13. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004;109:2566-2571. (Pubitemid 38720558)
14. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534. (Pubitemid 32521959)
15. Zhang R, Zhang YY, Huang XR, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 2010;55:953-960.
16. Schwedler SB, Guderian F, Dammrich J, et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 2003;18:2300-2307. (Pubitemid 37336817)
17. Stuveling EM, Hillege HL, Bakker SJ, et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003;63:654-661. (Pubitemid 36126812)
18. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911. (Pubitemid 29197978)
19. Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004;140:9-17.
20. Ciliberto G, Arcone R, Wagner EF, et al. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J 1987;6:4017-4022.
21. Szalai AJ, van Ginkel FW, Dalrymple SA, et al. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol 1998;160:5294-5299. (Pubitemid 28267816)
22. Wang W, Huang XR, Li AG, et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005;16:1371-1383. (Pubitemid 41716521)
23. Huang XR, Chung AC, Wang XJ, et al. Mice overexpressing latent TGFbeta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 2008;295:F118-F127.
24. Chung AC, Huang XR, Zhou L, et al. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009;24:1443-1454.
25. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 2010;21:249-260.
26. Lan HY, Mu W, Nikolic-Paterson DJ, et al. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 1995;43:97-102.
27. Xing D, Hage FG, Chen YF, et al. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc\{gamma\}RI)-dependent. Am J Pathol 2008;172:22-30. (Pubitemid 351186364)
28. Mold C, Du Clos TW. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptors. J Immunol 2006;176:7598-7604. (Pubitemid 43853054)
29. Verma S, Badiwala MV, Weisel RD, et al. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886-1891. (Pubitemid 38020747)
30. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-217. (Pubitemid 43323069)
31. Chen Y, Wang J, Yao Y, et al. CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 2009;583: 2811-2818.
32. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005;10:48-56. (Pubitemid 40349406)
33. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007;22:2011-2022. (Pubitemid 50001040)
34. Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003;14:1535-1548. (Pubitemid 36687055)
35. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361-368.
36. Liang YJ, Shyu KG, Wang BW, et al. C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 2006;40:412-420.
37. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13:2600-2610.
38. Schnaper HW, Hayashida T, Poncelet AC. It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 2002;13: 1126-1128. (Pubitemid 34274113)
39. Terada Y, Hanada S, Nakao A, et al. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in postobstructed kidney. Kidney Int 2002;61:94-98.
40. Li JH, Zhu HJ, Huang XR, et al. Smad7 inhibits fibrotic effect of TGFBeta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002;13:1464-1472. (Pubitemid 34579235)
41. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factorbeta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005;166:761-771. (Pubitemid 40315633)
42. Sato M, Muragaki Y, Saika S, et al. Targeted disruption of TGF-beta1/ Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112:1486-1494. (Pubitemid 38056275)
43. Li JH, Lv KY, Li HY, et al. Suppressed acute phase response to LPSinduced hepatic injury in Smad3-deficient mice. Mol Immunol 2009;46:362-365.
44. Taylor AW, Ku NO, Mortensen RF. Regulation of cytokine-induced human C-reactive protein production by transforming growth factorbeta. J Immunol 1990;145:2507-2513. (Pubitemid 20374571)
45. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated Creactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
46. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with Creactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.